Citation: H. Allain et al., Efficacy and safety of zolpidem administered - 'As needed' in primary insomnia results of a double-blind, placebo-controlled study, CLIN DRUG I, 21(6), 2001, pp. 391-400
Authors:
Bentue-Ferrer, D
Reymann, JM
Tribut, O
Allain, H
Vasar, E
Bourin, M
Citation: D. Bentue-ferrer et al., Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam, EUR NEUROPS, 11(1), 2001, pp. 41-50
Authors:
Le Cavorzin, P
Poudens, SA
Chagneau, F
Carrault, G
Allain, H
Rochcongar, P
Citation: P. Le Cavorzin et al., A comprehensive model of spastic hypertonia derived from the pendulum testof the leg, MUSCLE NERV, 24(12), 2001, pp. 1612-1621
Authors:
Biraben, A
Allain, H
Scarabin, JM
Schuck, S
Edan, G
Citation: A. Biraben et al., Exacerbation of juvenile myoclonic epilepsy with lamotrigine - Reply from the authors, NEUROLOGY, 56(10), 2001, pp. 1424-1425
Authors:
Allain, H
Dautzenberg, PHJ
Maurer, K
Schuck, S
Bonhomme, D
Gerard, D
Citation: H. Allain et al., Double blind study of tiapride versus haloperidol and placebo in agitationand aggressiveness in elderly patients with cognitive impairment, PSYCHOPHAR, 148(4), 2000, pp. 361-366
Citation: H. Allain et al., Depression in Parkinson's disease - Must be properly diagnosis and treatedto avoid serious morbidity, BR MED J, 320(7245), 2000, pp. 1287-1288
Authors:
Patat, A
Rosenzweig, P
Enslen, M
Trocherie, S
Miget, N
Bozon, MC
Allain, H
Gandon, JM
Citation: A. Patat et al., Effects of a new slow release formulation of caffeine on EEG, psychomotor and cognitive functions in sleep-deprived subjects, HUM PSYCHOP, 15(3), 2000, pp. 153-170
Authors:
Schuck, S
Allain, H
Lebeux, P
Chaperon, J
Citation: S. Schuck et al., Antidepressant prescription practices in a population of hospital psychiatrists and non-psychiatrists, PRESSE MED, 29(7), 2000, pp. 357-362
Authors:
Allain, H
Destee, A
Petit, H
Patay, M
Schuck, S
Bentue-Ferrer, D
Le Cavorzin, P
Citation: H. Allain et al., Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease, EUR NEUROL, 44(1), 2000, pp. 22-30
Authors:
Allain, H
Schuck, S
Lebreton, S
Strenge-Hesse, A
Braun, W
Gandon, JM
Brissot, P
Citation: H. Allain et al., Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease, DEMENT G C, 10(3), 1999, pp. 181-185
Authors:
Agid, Y
Destee, A
Durif, F
Montastruc, JL
Pedarriosse, AM
Deptula, D
Hoffman-La Roche, F
Pollak, P
Bonnet, AM
Allain, H
le Cavorzin, P
Barroche, G
Blin, O
Cesaro, P
Chazot, G
Broussolle, E
Leduc, V
Debilly, B
Feve, JR
Geraud, G
Fabre, N
Gu, C
Gil, R
Henry, P
Tison, F
Ansquer, O
Brefel, C
Payen, I
Said, G
Plante, V
Touchon, J
Cesari, JB
Camu, W
Bennys, K
Viallet, F
Warter, JM
Tranchant, C
Ziegler, M
Citation: Y. Agid et al., Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients, MOVEMENT D, 14(1), 1999, pp. 38-44
Authors:
Patat, A
Rosenzweig, P
Miget, N
Allain, H
Gandon, JM
Citation: A. Patat et al., Effects of 50mg amisulpride on EEG, psychomotor and cognitive functions inhealthy sleep-deprived subjects, FUN CL PHAR, 13(5), 1999, pp. 582-594
Authors:
Patat, A
Chaufour, S
Gandon, JM
Allain, H
Rosenzweig, P
Citation: A. Patat et al., Safety and pharmacodynamics of single ascending doses of SL34.0026, a new reversible and selective MAO-B inhibitor in healthy subjects, BR J CL PH, 47(5), 1999, pp. 584-585